Cartesian Therapeutics, Inc. (RNAC)
RNAC Stock Price Chart
Explore Cartesian Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze RNAC price movements and trends.
RNAC Company Profile
Discover essential business fundamentals and corporate details for Cartesian Therapeutics, Inc. (RNAC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Jun 2016
Employees
75.00
CEO
Carsten Brunn
Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
RNAC Financial Timeline
Browse a chronological timeline of Cartesian Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.83, while revenue estimate is $179.67k.
Earnings released on 30 Apr 2026
EPS came in at -$1.46 falling short of the estimated -$0.84 by -73.81%, while revenue for the quarter reached $78.00k , missing expectations by -64.51%.
Earnings released on 9 Mar 2026
EPS came in at -$1.38 falling short of the estimated -$0.82 by -68.29%, while revenue for the quarter reached $947.00k , beating expectations by +529.93%.
Earnings released on 6 Nov 2025
EPS came in at -$1.38 falling short of the estimated -$0.81 by -70.37%, while revenue for the quarter reached $452.00k , beating expectations by +69.71%.
Earnings released on 7 Aug 2025
EPS came in at $0.50 surpassing the estimated -$0.76 by +165.79%, while revenue for the quarter reached $298.00k , missing expectations by -67.91%.
Earnings released on 8 May 2025
EPS came in at -$0.68 falling short of the estimated -$0.61 by -11.48%, while revenue for the quarter reached $1.10m , beating expectations by +20.00%.
Earnings released on 20 Mar 2025
EPS came in at -$0.59 surpassing the estimated -$0.78 by +24.36%, while revenue for the quarter reached $759.00k , missing expectations by -24.10%.
Earnings released on 7 Nov 2024
EPS came in at -$1.13 falling short of the estimated -$0.78 by -44.87%, while revenue for the quarter reached $387.00k , missing expectations by -69.04%.
Earnings released on 8 Aug 2024
EPS came in at $0.54 surpassing the estimated -$0.86 by +162.58%, while revenue for the quarter reached $33.27m , beating expectations by +403.34%.
Earnings released on 8 May 2024
EPS came in at -$10.50 falling short of the estimated -$0.89 by -1.09k%, while revenue for the quarter reached $5.84m , beating expectations by +250.40%.
Stock split effective on 5 Apr 2024
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Mar 2024
EPS came in at -$2.17 falling short of the estimated -$0.04 by -5.32k%, while revenue for the quarter reached $8.27m , beating expectations by +230.64%.
Earnings released on 13 Nov 2023
EPS came in at -$1.35 surpassing the estimated -$2.10 by +35.71%, while revenue for the quarter reached $5.88m , missing expectations by -18.74%.
Earnings released on 17 Aug 2023
EPS came in at -$2.10 surpassing the estimated -$3.60 by +41.67%, while revenue for the quarter reached $5.25m , missing expectations by -6.27%.
Earnings released on 4 May 2023
EPS came in at -$4.20 falling short of the estimated -$2.60 by -61.54%, while revenue for the quarter reached $5.94m , missing expectations by -51.08%.
Earnings released on 2 Mar 2023
EPS came in at $1.20 surpassing the estimated -$2.17 by +155.30%, while revenue for the quarter reached $16.80m , beating expectations by +43.74%.
Earnings released on 3 Nov 2022
EPS came in at -$1.50 falling short of the estimated -$0.17 by -774.99%, while revenue for the quarter reached $20.71m , missing expectations by -17.86%.
Earnings released on 4 Aug 2022
EPS came in at $1.80 surpassing the estimated -$2.27 by +179.25%, while revenue for the quarter reached $39.30m , beating expectations by +185.17%.
Earnings released on 5 May 2022
EPS came in at $6.90 surpassing the estimated -$3.35 by +305.91%, while revenue for the quarter reached $34.00m , beating expectations by +180.08%.
RNAC Stock Performance
Access detailed RNAC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
